Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 74-84, 2012.
Article
in English
| WPRIM
| ID: wpr-192123
ABSTRACT
Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Combined Modality Therapy
/
Carcinoma, Non-Small-Cell Lung
/
Precision Medicine
/
ErbB Receptors
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS